Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2003
06/12/2003US20030109449 Gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonist of glucogen-like
06/12/2003US20030109448 Enhancing cellular uptake and redistributing gene regulating polyamides from the extranuclear areas in eukaryotic cells to the nucleus thereof. The method consists of administering to the eukaryotic cells a molecular trafficking compound
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109435 Methods of inhibiting amyloid toxicity
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030109417 Administering substance P receptor antagonist selected from the group consisting of L 742694, L 758298, and LY 303241, a non-toxic magnesium compound and a pharmaceutically acceptable vehicle
06/12/2003US20030109039 Enriched central nervous system stem cell and porgenitor cell populations, and methods for identifying, isolating and enriching for such populations
06/12/2003US20030109022 Asp2
06/12/2003US20030108965 Using polypeptide, detection of antibody; cancer of ovaries
06/12/2003US20030108953 Truncated egf receptor
06/12/2003US20030108928 MID 241 receptor, a novel G-protein coupled receptor
06/12/2003US20030108923 Blocking gene expression
06/12/2003US20030108623 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils as synergists for conventional treatments
06/12/2003US20030108622 Prophylactic or therapeutic treatment of soft tissue cancer, e.g. breast cancer; improving the effective treatment and reducing the adverse side effects of current anticancer therapy; antiproliferative, -carcinogenic agents
06/12/2003US20030108588 Reduce restenosis coating on medical device
06/12/2003US20030108575 Stabilized oral suspension formulation
06/12/2003US20030108540 Inducing apoptosis in tissues; binding antibodies
06/12/2003US20030108527 Maturation-promoting agent for immature dendrtic cells
06/12/2003US20030108521 Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
06/12/2003US20030108518 TRX1 antibody and uses therefor
06/12/2003US20030108510 Synergistic mixture of rutin, escin and bufemin; branching of arteries, veins
06/12/2003US20030108493 Extracts from residues left in the production of wine
06/12/2003CA2537913A1 Prevention and treatment of androgen-deprivation induced osteoporosis
06/12/2003CA2471794A1 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
06/12/2003CA2469385A1 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
06/12/2003CA2469228A1 Azole compound and medicinal use thereof
06/12/2003CA2469223A1 Trioxane derivatives as antimalaria or anticancer compounds
06/12/2003CA2469193A1 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
06/12/2003CA2469130A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
06/12/2003CA2469093A1 A novel herbal chemical composition for the treatment of cancer
06/12/2003CA2469078A1 Immunotherapeutic methods and systems
06/12/2003CA2468996A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
06/12/2003CA2468927A1 Ring fused pyrazole derivatives
06/12/2003CA2468846A1 Peroxisome proliferator activated receptor agonists
06/12/2003CA2468839A1 Methods of treating cancer using an fpt inhibitor and anti neoplastic agents
06/12/2003CA2468745A1 Induction of apoptosis in cancer cells
06/12/2003CA2468676A1 Combination of a selective pde4 inhibitor and an adrenergic beta-2 receptor agonist
06/12/2003CA2468525A1 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers of 4-[4-[(1r)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3s)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]
06/12/2003CA2468463A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
06/12/2003CA2468067A1 Metabotropic glutamate receptor-5 modulators
06/12/2003CA2468044A1 Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith
06/12/2003CA2467435A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/12/2003CA2466751A1 Ep4 receptor agonist, compositions and methods thereof
06/12/2003CA2466649A1 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
06/12/2003CA2463794A1 Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof
06/11/2003EP1318150A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
06/11/2003EP1318147A1 Novel pyrimidine derivative and novel pyridine derivative
06/11/2003EP1317930A1 Antithrombin for prevention and therapy of vascular proliferative diseases
06/11/2003EP1317929A2 Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis c infection
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317922A1 Antipyretic preparation containing xylitol
06/11/2003EP1317540A2 Imidazoline receptor homologs
06/11/2003EP1317537A2 G-csf analog compositions and methods
06/11/2003EP1317489A1 A mixture of non-sulfated fucose-based oligosaccharides, a cosmetic or pharmaceutical composition comprising said mixture and its use in cosmetics or pharmacy
06/11/2003EP1317485A2 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
06/11/2003EP1317483A2 Variants of allergenic proteins of the group 2 of dermatophagoides
06/11/2003EP1317465A1 Purine derivatives
06/11/2003EP1317459A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
06/11/2003EP1317458A2 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2alpha antagonists
06/11/2003EP1317457A2 INTERHETEROARYL 7-OXABICYCLIC 2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F 2$g(a)? ANTAGONISTS
06/11/2003EP1317456A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317453A1 Isoxazoles and their use as inhibitors of erk
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317446A1 Oxindole derivatives
06/11/2003EP1317445A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317443A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317442A1 Quinolinone derivatives as tyrosine kinase inhibitors
06/11/2003EP1317433A2 Inhibitors of glycogen synthase kinase 3
06/11/2003EP1317432A1 Piperidine derivatives for use as 2,3-oxidosqualene-lanosterol cyclase inhibitors
06/11/2003EP1317430A1 (2-azabicyclo 2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
06/11/2003EP1317429A1 Amidine inhibitors of serine proteases
06/11/2003EP1317425A2 Resorcinol derivatives
06/11/2003EP1317424A2 Polyamine analogues as therapeutic and diagnostic agents
06/11/2003EP1317421A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317420A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317418A2 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317417A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317414A2 Gamma-ketoacid dipeptides as inhibitors of caspase-3
06/11/2003EP1317283A2 Tweak receptor agonists as anti-angiogenic agents
06/11/2003EP1317277A2 Antifungal combination therapy
06/11/2003EP1317274A2 Peptide composition for treatment of periodontal diseases and prevention of skin aging
06/11/2003EP1317272A2 Composition for improving the cell protection comprising a lipophilic antioxidant an a hydrophilic antioxidant
06/11/2003EP1317270A1 Exemestane for the treatment of oestrogen-dependent cancers
06/11/2003EP1317267A2 Compositions containing diacyltartaric salts of (e)-metanicotine
06/11/2003EP1317266A2 Neuroprotective 2-pyridinamine compositions and related methods
06/11/2003EP1317265A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
06/11/2003EP1317258A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
06/11/2003EP1317252A2 Pharmaceutical composition having specific water activity
06/11/2003EP1228077B1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities
06/11/2003EP1062349B1 Diisopropyl fluorophosphatase and the utilization and production thereof
06/11/2003EP1060161B1 Matrix metalloproteinase inhibitors
06/11/2003EP1021413B1 The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
06/11/2003EP0973741B1 S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide as a 5-ht2 receptor antagonist
06/11/2003EP0954325B1 Method for the specific immunoadsorption of selected pathogenic factors in the treatment of aids
1 ... 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 ... 1564